Non-Alchoholic Fatty Liver Disease. Nonalcoholic steatohepatitis (NASH)
Conditions
Interventions
Intervention 1: Intervention group: Patients with Non-Alcoliholic Fatty Liver disease and type 2 Diabetes are under intervention with Empagliflozine at a dose of 10 and 25 mg based on FBS and HbA1c f
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients with type 2 diabetes in the age group of 20 to 70 years who are candidates for treatment with Empagliflozine No history of using Empaglifozine GFR>35ml/min/1.7m2 HbA1c=7.5% Satisfaction of patients or their legal guardians to attend the study and continue it
Exclusion criteria
Exclusion criteria: History of advanced liver and kidney disease Cardiac surgery or angioplasty planned within the last 3 months Bariatric surgery in last 2 years and other gastrointestinal surgeries that cause chronic malabsorotion Bleeding or any disorder in causing hemolysis or unstable red blood cells(such as malaria) Medical history of cancer(except basal cell cancer)or cancer treatment in the last 5 years treatment with anti-obesity drugs in the 3 months prior ti informed consent or any other treatment at the time of screening(i.e. surgery;aggressive dieting;etc)that results in an unstable body weight current treatment with systemic steroids or any uncontrolled endocrine disorder other than type 2 diabetes cinsumtion of alcohol or drugs in the last 3 months patients who during the treatment,another drug to control blood sugar was added to their teatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Degree of fatty liver in MRI. Timepoint: Before treatment and six months after treatment. Method of measurement: MRI.;Body mass index. Timepoint: before and three and six monthns after treatment. Method of measurement: Kg/m2.;Fasting blood sugar. Timepoint: before and three and six months after treatmen. Method of measurement: blood sampling.;HbA1C. Timepoint: before and three and six months after teatment. Method of measurement: blood sampling.;The level of liver transaminases. Timepoint: before and three and six months after treatmenet. Method of measurement: blood sampling. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFateme Shojaee
Shahid Beheshti University of Medical Sciences
Outcome results
None listed